130 related articles for article (PubMed ID: 31494331)
1. Clinicopathological and prognostic significance of CXCR4 high expression in renal cell carcinoma: A meta-analysis and literature review.
Si X; Ma J; Yu F; Zhao H; Huang H; Sun YW
Int J Surg; 2019 Nov; 71():12-18. PubMed ID: 31494331
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance of CXCR4 expression in renal cell carcinoma: a meta-analysis.
Tang B; Tang F; Li Y; Yuan S; Li B; Wang Z; He S
Ann Surg Oncol; 2015 Mar; 22(3):1026-31. PubMed ID: 25249257
[TBL] [Abstract][Full Text] [Related]
3. Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis.
Cheng B; Yang G; Jiang R; Cheng Y; Yang H; Pei L; Qiu X
Oncotarget; 2016 Oct; 7(40):65862-65875. PubMed ID: 27588469
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of High CXCR4 Expression in Renal Cell Carcinoma: A System Review and Meta-Analysis.
Du Y; Long Q; Guan B; Mu L
Dis Markers; 2015; 2015():568980. PubMed ID: 26526157
[TBL] [Abstract][Full Text] [Related]
5. Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases.
Maas M; Kurcz A; Hennenlotter J; Scharpf M; Fend F; Walz S; Stühler V; Todenhöfer T; Stenzl A; Bedke J; Rausch S
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982302
[TBL] [Abstract][Full Text] [Related]
6. Association of CXCL12 and CXCR4 gene polymorphisms with the susceptibility and prognosis of renal cell carcinoma.
Cai C; Wang LH; Dong Q; Wu ZJ; Li MY; Sun YH
Tissue Antigens; 2013 Sep; 82(3):165-70. PubMed ID: 24032722
[TBL] [Abstract][Full Text] [Related]
7. microRNA‑572 functions as an oncogene and a potential biomarker for renal cell carcinoma prognosis.
Pan X; Li Z; Zhao L; Quan J; Zhou L; Xu J; Xu W; Guan X; Li H; Yang S; Gui Y; Lai Y
Oncol Rep; 2018 Nov; 40(5):3092-3101. PubMed ID: 30132566
[TBL] [Abstract][Full Text] [Related]
8. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis.
Pan J; Mestas J; Burdick MD; Phillips RJ; Thomas GV; Reckamp K; Belperio JA; Strieter RM
Mol Cancer; 2006 Nov; 5():56. PubMed ID: 17083723
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancer.
Zhang C; Li J; Han Y; Jiang J
Drug Des Devel Ther; 2015; 9():3267-78. PubMed ID: 26150700
[TBL] [Abstract][Full Text] [Related]
10. CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis.
Gassenmaier M; Chen D; Buchner A; Henkel L; Schiemann M; Mack B; Schendel DJ; Zimmermann W; Pohla H
Stem Cells; 2013 Aug; 31(8):1467-76. PubMed ID: 23630186
[TBL] [Abstract][Full Text] [Related]
11. Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma.
Rasti A; Abolhasani M; Zanjani LS; Asgari M; Mehrazma M; Madjd Z
J Cancer Res Clin Oncol; 2017 Jan; 143(1):95-104. PubMed ID: 27638770
[TBL] [Abstract][Full Text] [Related]
12. High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.
D' Alterio C; Portella L; Ottaiano A; Rizzo M; Carteni G; Pignata S; Facchini G; Perdona S; Di Lorenzo G; Autorino R; Franco R; La Mura A; Nappi O; Castello G; Scala S
Curr Cancer Drug Targets; 2012 Jul; 12(6):693-702. PubMed ID: 22463589
[TBL] [Abstract][Full Text] [Related]
13. Expression profiling and clinicopathological significance of DNA methyltransferase 1, 3A and 3B in sporadic human renal cell carcinoma.
Li M; Wang Y; Song Y; Bu R; Yin B; Fei X; Guo Q; Wu B
Int J Clin Exp Pathol; 2014; 7(11):7597-609. PubMed ID: 25550796
[TBL] [Abstract][Full Text] [Related]
14. High CXC chemokine receptor 4 expression is an adverse prognostic factor in patients with clear-cell renal cell carcinoma.
An H; Xu L; Zhu Y; Lv T; Liu W; Liu Y; Liu H; Chen L; Xu J; Lin Z
Br J Cancer; 2014 Apr; 110(9):2261-8. PubMed ID: 24714746
[TBL] [Abstract][Full Text] [Related]
15. Differential role of CD133 and CXCR4 in renal cell carcinoma.
D'Alterio C; Cindolo L; Portella L; Polimeno M; Consales C; Riccio A; Cioffi M; Franco R; Chiodini P; Cartenì G; Mirone V; Longo N; Marra L; Perdonà S; Claudio L; Mascolo M; Staibano S; Falsaperla M; Puglisi M; Martignoni G; Ficarra V; Castello G; Scala S
Cell Cycle; 2010 Nov; 9(22):4492-4500. PubMed ID: 21127401
[TBL] [Abstract][Full Text] [Related]
16. Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer.
D'Alterio C; Consales C; Polimeno M; Franco R; Cindolo L; Portella L; Cioffi M; Calemma R; Marra L; Claudio L; Perdonà S; Pignata S; Facchini G; Cartenì G; Longo N; Pucci L; Ottaiano A; Costantini S; Castello G; Scala S
Curr Cancer Drug Targets; 2010 Nov; 10(7):772-81. PubMed ID: 20578990
[TBL] [Abstract][Full Text] [Related]
17. LncRNAs act as prognostic and diagnostic biomarkers in renal cell carcinoma: a systematic review and meta-analysis.
Chen J; Chen Y; Gu L; Li X; Gao Y; Lyu X; Chen L; Luo G; Wang L; Xie Y; Duan J; Peng C; Ma X
Oncotarget; 2016 Nov; 7(45):74325-74336. PubMed ID: 27527868
[TBL] [Abstract][Full Text] [Related]
18. miR-566 functions as an oncogene and a potential biomarker for prognosis in renal cell carcinoma.
Pan X; Quan J; Li Z; Zhao L; Zhou L; Jinling X; Weijie X; Guan X; Li H; Yang S; Gui Y; Lai Y
Biomed Pharmacother; 2018 Jun; 102():718-727. PubMed ID: 29604591
[TBL] [Abstract][Full Text] [Related]
19. A 17-Gene Signature Predicted Prognosis in Renal Cell Carcinoma.
Li F; Hu W; Zhang W; Li G; Guo Y
Dis Markers; 2020; 2020():8352809. PubMed ID: 32184905
[TBL] [Abstract][Full Text] [Related]
20. CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.
Krieg A; Riemer JC; Telan LA; Gabbert HE; Knoefel WT
PLoS One; 2015; 10(6):e0130192. PubMed ID: 26091099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
